BLUE BELL, Pa., Feb. 22, 2012 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its next generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to skin in…
View full post on PR Newswire: Medical Pharmaceuticals
















































